Edwards Lifesciences (NYSE:EW) Updates Q1 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its first quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.700-0.760 for the period, compared to the consensus earnings per share estimate of 0.690. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Barclays reissued an “overweight” rating and issued a $104.00 price target (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $96.77.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.20 on Tuesday, hitting $77.00. The stock had a trading volume of 6,543,660 shares, compared to its average volume of 4,197,906. The stock has a market cap of $44.68 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 3.03 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89. The company’s 50 day moving average price is $83.98 and its 200 day moving average price is $81.16.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.03). Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at $2,729,984.20. This trade represents a 26.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 43,804 shares of company stock valued at $3,699,082 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Edwards Lifesciences by 9.0% during the 3rd quarter. Invesco Ltd. now owns 3,570,216 shares of the medical research company’s stock valued at $277,656,000 after buying an additional 294,175 shares during the period. Viking Global Investors LP acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $238,688,000. AQR Capital Management LLC boosted its holdings in Edwards Lifesciences by 114.5% in the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after acquiring an additional 1,111,139 shares during the period. Finally, Man Group plc boosted its holdings in Edwards Lifesciences by 19.0% in the 3rd quarter. Man Group plc now owns 1,967,433 shares of the medical research company’s stock worth $153,007,000 after acquiring an additional 313,494 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.